

## PERFORMANCE IN DELIVERING CLINICAL RESEARCH (Q4, 2013/14)

Research Ethics Committee Reference Number	Name of Trial	Target number of patients	Date agreed to recruit target number of patients	Trial status	Target met within the agreed time?	Comments
07/H0304/91	A Randomised, 4-arm, placebo-controlled phase 2 trial of AMG 386 in combination with bevacizumab and paclitaxel or AMG 386 plus paclitaxel as first-line therapy in subjects with Her-2-negative, metastatic or locally recurrent breast cancer			Closed - In Follow Up	N/A	No Target and no Date agreed.
07/H1102/84	Sunitinib treatment of renal adjuvant cancer (S-TRAC) A randomised double blind phase 3 study of adjuvant vs placebo in subjects at high risk of recurrent RCC	3		Closed - In Follow Up	Y	Study has delivered.
07/H1211/171	A Phase 1/2 Study of SKI-606 in Patients with Philadelphia Chromosome Positive (Ph+) Chronic Myeloid or Acute Lymphoblastic Leukaemia, who are Resistant to or Intolerant of Imatinib or Dasatinib			Closed - In Follow Up	N/A	No Target and no Date agreed.
07/Q1206/53	Clinical Trial Protocol CAMN107A2303 - A phase III multi-center, open-label, randomized study of imatinib versus nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (C)	5	15/06/2008	Closed - In Follow Up	Y	Study has delivered to time and target.
08/H1010/66	Protocol H3E-MC-JMIG - Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients with Unresect	5	01/01/2011	Closed - In Follow Up	N	
08/H1102/75	A double-blind, randomized, multicenter, placebo controlled, parallel-group study comparing the efficacy and safety of 0.5mg FTY720 administered orally once daily versus placebo in patients with primary progressive multiple sclerosis	10	01/12/2011	Closed - In Follow Up	Y	Study has delivered to time and target.
08/S0703/171	Effect of liraglutide on body weight in non-dabetic obese subjects or overweight subjects with comorbidities A randomised, double blind, placebo controlled, parallel group, multi centre, multinational trial with stratification of subject to either	20	02/11/2011	Closed - In Follow Up	Y	Study has delivered to time and target.
09/H0405/51	A Phase II Study of Dasatinib therapy in children & adolescents with PH+ leukaemia with resistance or intolerance to Imatinib.			Open	N/A	No Target and no Date agreed.
09/H0505/98	A multicenter, Double-blind, Randomised, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of a single treatment of BOTOX(Botulinum Toxin Type A) Purified Neurotoxin Complex Followed by a treatment with Botox as applicable in patie			Closed - Follow Up Complete	N/A	No Target and no Date agreed.
09/H0711/8	CompERA-XL: Comparison of endothelin receptor antagonist therapy in routine care	200		Open	N/A	No Date agreed with Sponsor.
1/LO/0671	A Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Study 205MS301			Closed - In Follow Up	N/A	No Target and no Date agreed.
10/H0406/27	Randomised, Multicentre, Open-label, Phase III Study of Plitidepsin in Combination with Dexamethasone vs. Dexamethasone Alone in Patients with Relapsed/Refractory Multiple Myeloma	6		Open	N/A	No Date agreed with Sponsor.
10/H0605/58	Sub Study to study WN25203, using positron emission tomography (PET) with an amyloid tracer to assess changes in amyloid load over time in subjects with Prodromal Alzheimer's Disease	1	30/09/2012	Closed - In Follow Up	Y	Study has delivered to time and target.
10/H0605/59	Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease (WN25203)	6	01/09/2013	Closed - In Follow Up	Y	Study has delivered to time and target.
10/H0711/11	Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active control Study to Determine the Efficacy and safety of Daclizumab High Yield Process (DAC HYP) versus Avonex? (Interferon ?-1a) in patients with Relapsing-remitting multiple	6	01/11/2011	Closed - In Follow Up	Y	Study has delivered to time and target.
10/H0713/35	An International, multi-center, randomized, controlled trial evaluating the effect of xenon on post-operative delirium in elderly patients undergoing hip fracture surgery	6	31/10/2014	Open	Y	Date agreed to recruit to target not yet passed, but study has already delivered to time and target.

10/H0713/88	A Pivotal Phase 2 Trial of Ponatinib (AP24534) in Patients with Refractory Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia.	350	30/09/2011	Closed - In Follow Up	N	
10/H0715/57	A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy	5	01/11/2011	Closed - In Follow Up	Y	Study has delivered to time and target.
10/H0715/77	Phase II trial of cediranib +/-gefitinib for recurrent glioblastoma - DORIC	15		Closed - In Follow Up	Y	Study has delivered.
10/H0717/68	A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212/Inactivated Varicella-Zoster Virus (VZV) Vaccine in Recipients of Autologous Hematopoietic	15	30/11/2011	Closed - In Follow Up	N	
10/H0904/49	A single arm, open-label, multicenter study evaluating the long-term safety, tolerability and efficacy of 0.5mg fingolimod (FTY720) administered orally once daily in patients with multiple sclerosis	10	01/12/2011	Closed - In Follow Up	Y	Study has delivered to time and target.
10/H1002/27	A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence (D-CARE)	20	01/11/2012	Closed - In Follow Up	N	
10/H1211/20	LEADER, liraglutide cardiovascular outcome study in type 2 diabetes	20	01/03/2012	Closed - In Follow Up	N	
10/H1306/5	A phase III open multicentre study to investigate the safety and efficacy of BPL's high purity factor X in the treatment of factor X deficient subjects undergoing surgery.	1	31/12/2012	Closed - In Follow Up	Y	Study has delivered to time and target.
10/NIRO2/45	A phase-3, multi-centre, randomized, double-blind, placebo-controlled, parallel-group study to compare efficacy and safety of Pomalidomide versus placebo in subjects with MPN-associated myelofibrosis and red blood cell-transfusion-dependence.	5		Closed - In Follow Up	N/A	No Date agreed with Sponsor.
11/AL/0120	AN OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 STUDY OF S-1 AND CISPLATIN COMPARED WITH 5-FU AND CISPLATIN IN PATIENTS WITH METASTATIC DIFFUSE GASTRIC CANCER PREVIOUSLY UNTREATED WITH CHEMOTHERAPY	3	06/07/2014	Open	N/A	Date agreed to recruit to target not yet passed.
11/AL/0322	Phase 2 Active-controlled Double-Blind Trial of Dasatinib Added to Gemcitabine for Subjects with Locally-Advanced Pancreatic Cancer	2	30/10/2012	Closed - In Follow Up	Y	Study has delivered to time and target.
11/EE/0256	Multi-centre, open label, prospective, consecutive series registry database of BioPoly RS Partial Resurfacing Knee implant	10	31/12/2014	Open	N/A	Date agreed to recruit to target not yet passed.
11/EM/0074	A 2-Year, multicenter, double-masked, randomised, parallel study of the safety of LUMIGAN 0.1 mg/mL compared with LUMIGAN 0.3 mg/mL in patients with glaucoma or ocular hypertension	15	31/12/2013	Closed - In Follow Up	N	
11/EM/0305	A Phase 3 Multicentre, Randomised, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Adolescent Subjects with Moderate to Severe Plaque-type Psoriasis (CADMUS)	2	31/10/2013	Closed - In Follow Up	N	
11/H0502/12	An open label, phase II trial of BIBW 2992 (afatinib) in patients with metastatic HER2-overexpressing breast cancer failing HER2-targeted treatment in the neoadjuvant and/or adjuvant treatment setting	20	30/04/2012	Closed - Follow Up Complete	N	
11/LO/0190	A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy	8	15/12/2012	Closed - In Follow Up	Y	Study has delivered to time and target.
11/LO/0449	A multicenter, global, randomized, double-blind study of axitinib versus placebo in patients with advanced hepatocellular carcinoma following failure of one prior antiangiogenic therapy	2	30/06/2012	Closed - In Follow Up	Y	Study has delivered to time and target.
11/LO/0537	A Multicenter, randomized, double-blind, placebo-controlled Study of the Efficacy of Natalizumab or Reducing Disability Progression in Subjects with Secondary Progressive Multiple Sclerosis	20	29/03/2013	Closed - In Follow Up	Y	Study has delivered to time and target.
11/LO/1023	A 12Month, Multicentre, Randomised, Parallel Group Study to Compare the Efficacy and Safety of Ozurdex Versus Lucentis in Patients with Branch Retinal Vein Occlusion	10	31/10/2013	Closed - In Follow Up	N	

11/LO/1040	A long-term monitoring study to evaluate the persistence of direct acting antiviral (DAA) treatment-resistant mutations or the durability of sustained virological response (SVR) in patients treated with DAA-containing regimens for chronic hepatitis	2		Open	Y	Study has delivered.
11/LO/1369	A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy	3	01/12/2013	Open	N	Rare disease.
11/LO/1415	A multicentre, double-blind, randomised, placebo controlled study to determine the efficacy and tolerability of OXN PR for the treatment of severe Parkinson's disease associated pain	4	02/06/2013	Closed - Follow Up Complete	Y	Study has delivered to time and target.
11/LO/1502	A Phase 3, Randomized, Double-Blinded, Placebo Controlled 3 arm Study of SAR302503 in Patients with Intermediate-2 or High Risk Primary (PMF), Post Polycythemia Vera (post PV-MF), or Post-Essential Thrombocythemia Myelofibrosis (post ET-MF) with Spl	2	09/12/2015	Closed - In Follow Up	Y	Date agreed to recruit to target not yet passed, but study has already delivered to time and target.
11/LO/1503	A Randomized Phase II, Open-Label study of the Efficacy and Safety of Orally Administered SAR302503 in patients with polycythemia vera (PV) or essential thrombocythemia (ET) who are resistant or intolerant to hydroxyurea.	2	12/03/2015	Closed - In Follow Up	Y	Date agreed to recruit to target not yet passed, but study has already delivered to time and target.
11/LO/1739	NV27779 - A phase II randomized, double-blind multicenter active-controlled parallel group study to evaluate the sustained virological response of the HCV polymerase inhibitor pro-drug RO5024048 in combination with Telaprevir and Pegasys/Copegus com	5	01/09/2013	Closed - In Follow Up	Y	Study has delivered to time and target.
11/LO/1904	A randomized double-blind multiple-dose placebo-controlled trial to establish the efficacy of QBX258 (combination of VAK694 and QAX576) in asthma that is inadequately controlled with inhaled corticosteroids and long acting beta agonists	6		Open	N/A	No Date agreed with Sponsor.
11/LO/2042	A Phase 2 open label biomarker study of angiotensin II type 2 receptor antagonist EMA401 for the treatment of pain in patients with chemotherapy-induced peripheral neuropathy	24	30/09/2013	Open	Y	Study has delivered to time and target.
11/NW/0298	A multicenter, phase III, open-label, randomized study in previously untreated patients with advanced indolent non Hodgkins Lymphoma comparing GA101 (RO5072759) plus chemotherapy with rituximab plus chemotherapy followed by GA101 or rituximab mainte	2	28/02/2022	Closed - In Follow Up	Y	Date agreed to recruit to target not yet passed, but study has already delivered to time and target.
11/NW/0690	Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)	8	31/07/2012	Closed - In Follow Up	N	
11/SC/0358	An Open-Label Re-treatment Study with Peg-Interferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Subjects With Chronic Hepatitis C (Clinical Protocol AI444026)	1	28/02/2014	Withdrawn	N/A	Study withdrawn by sponsor.
11/SC/0454	A phase IIIb parallel group, open label study of pegylated interferon alfa-2a monotherapy (PEG-IFN, RO 25-8310) compared to untreated control in children with HBeAg positive chronic hepatitis B	2	01/11/2014	Open	Y	Date agreed to recruit to target not yet passed, but study has already delivered to time and target.
11/WM/0279	Neural Cardiac Therapy for Heart Failure (NECTAR-HF) Research Study	10	31/12/2013	Closed - In Follow Up	N	
11/WS/0039	A Phase I/IIa trial of AZD4547 in combination with Cisplatin and Capecitabine (CX)	6	31/03/2015	Open	N/A	Date agreed to recruit to target not yet passed.
12/EE/0005	A multicentre, double blind, randomised controlled Clinical Investigation to validate the EPS1 device as a treatment for stroke induced dysphagia. A Study of Swallowing Treatment using Electrical Pharyngeal Stimulation (STEPS Study)	6	01/02/2014	Open	Y	Study has delivered to time and target.
12/EE/0176	Randomised, phase IV, placebo-controlled, comparative study to evaluate the efficacy and safety of tapering methotrexate (MTX) dosage versus maintaining the dosage in patients with severe active rheumatoid arthritis (RA) who have demonstrated an ina	5	01/01/2014	Open	N	
12/EE/0274	Tranexamic acid for the treatment of significant traumatic brain injury:an international randomised, double blind placebo controlled trial			Open	N/A	No Target and no Date agreed.
12/EE/0400	GS-US-334-0109 ? An open label study of GS-7977 + Ribavirin for 12 weeks in subjects with chronic HCV infection who participated in prior studies evaluating GS-7977	1		Closed - In Follow Up	N/A	No Date agreed with Sponsor.

12/EE/0499	A Phase II Randomized, Dose Ranging, Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Different Doses of MK-5172 When Administered Concomitantly with Peginterferon alfa-2b and Ribavirin in Treatment Na?ve Subjects with Chronic H	5		Closed - In Follow Up	Y	Study has delivered.
12/LO/0268	Open-Label, Phase 3b Study to Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Hepatitis C Virus Treatment-Na?ve and Treatment Experienced Subjects with Genotype 1 Chronic Hepatitis C and Human Immunodefici	4	01/03/2013	Closed - In Follow Up	N	
12/LO/0486	An Ascending Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of PF-05280602. A Recombinant Factor VIII Variant (813), in adult Hemophilia A and B Subjects with or without inhibitors	1	05/12/2013	Open	Y	Study has delivered to time and target.
12/LO/0720	A Phase 1 Randomised Study of MEDI-551 in Subjects with Relapsing-Remitting Multiple Sclerosis	4	30/06/2014	Suspended	N/A	Issues with study design - amendments submitted by sponsor
12/LO/0984	A Randomized, Open-Label Phase 2 Study Of The Ido Inhibitor Incb024360 Versus Tamoxifen For Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma Or Fallopian Tube Cancer Following Complete Remission With F	5	31/07/2014	Open	N/A	Date agreed to recruit to target not yet passed.
12/LO/1173	An Open Label Phase I/II Study of GSK2110183 in Combination with Carboplatin and Paclitaxel in Subjects with PlatinumResistant Ovarian Cancer	12	31/08/2014	Open	N/A	Date agreed to recruit to target not yet passed.
12/LO/1188	A Study of HSP90 Inhibitor AT13387 Alone or in Combination with Abiraterone Acetate in the Treatment of CastrationResistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone	2	30/09/2014	Withdrawn	N/A	Date agreed to recruit to target not yet passed.
12/LO/1320	Aneurysm Treatment using the HeliFX Aortic Securement System Global Registry	5	26/11/2013	Open	N	
12/LO/1343	A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating CNTO 3157 in Healthy Normal and Asthmatic Subjects Inoculated with Human Rhinovirus Type 16	2	09/09/2014	Open	Y	Date agreed to recruit to target not yet passed, but study has already delivered to time and target.
12/LO/1597	A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 co-administered with Ribavirin (RBV) in treatment ?experienced adults with genotype 1 chronic hepa	5	01/04/2013	Closed - In Follow Up	Y	Study has delivered to time and target.
12/LO/1598	A randomized, open label study to evaluate the safety and efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 (coadministered with Ribavirin (RBV) in adults with genotype 1 chronic hepatitis C virus (HCV) infection and cirrhosis (	4	31/03/2013	Closed - In Follow Up	Y	Study has delivered to time and target.
12/LO/1698	Valacyclovir in Delaying Antiretroviral Treatment Entry (VALIDATE) Short	10	31/12/2014	Open	N/A	Date agreed to recruit to target not yet passed.
12/LO/1748	A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed Dose Combination + Ribavirin for 12 and 24 weeks in Treatment-Na?ve Subjects with Chronic Genotype 1 HCV Infection	5	01/04/2014	Closed - Follow Up Complete	Y	Date agreed to recruit to target not yet passed, but study has already delivered to time and target.
12/LO/1762	Left ventricular MultiSpot Pacing for CRT (i-Spot)	8	29/05/2015	Open	N/A	Date agreed to recruit to target not yet passed.
12/LO/1823	A Randomized, Double-blind Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV 1 Infect	10	19/12/2013	Closed - In Follow Up	N	
12/LO/1861	A Randomised, Open-label, Active-controlled, Multi-centre Study to Evaluate the Safety of Rivaroxaban and Vitamin K Antagonists in Subjects Undergoing Catheter Ablation for Atrial Fibrillation	8	19/11/2013	Open	N	
12/LO/1981	A Randomized, Multicenter, Open-Label Phase III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine Versus Trastuzumab As Adjuvant Therapy For Patients With Her2-Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologi	3	01/03/2016	Open	Y	Date agreed to recruit to target not yet passed, but study has already delivered to time and target.

12/NE/0266	GS-US-334-0133 ? A phase 3 multicenter, randomised, double-blind, placebo-controlled study to investigate the efficacy and safety of GS-7977 + Ribavirin for 12 weeks in treatment naive and treatment experienced subjects with chronic genotype 2 or 3	5	01/09/2012	Closed - Follow Up Complete	Y	Study has delivered to time and target.
12/NE/0342	A multicentre, randomised, double blind, placebo-controlled pivotal study to evaluate the efficacy and safety of GFT505 80mg and GFT505 160mg on steatohepatitis in patients with non-alcoholic steatohepatitis (NASH)	6	01/02/2013	Withdrawn	N/A	Suspended and eventually withdrawn by sponsor.
12/NW/0137	A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung origin	5	03/11/2017	Closed - In Follow Up	Y	Date agreed to recruit to target not yet passed, but study has already delivered to time and target.
12/NW/0251	A multicentre, stratified, open, randomized, comparator-controlled, parallelgroup phase III study comparing treatment with 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in patients with inoperable, progressive, somatostatin receptor positive, midgut	5	01/06/2015	Open	N/A	Date agreed to recruit to target not yet passed.
12/NW/0555	Randomized Phase II Study of BEZ235 vs. everolimus in Advanced Pancreatic Neuroendocrine Tumors	2	15/04/2015	Open	N/A	Date agreed to recruit to target not yet passed.
12/NW/0682	A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDL-C in Subjects with Heterozygous Familial Hypercholesterolemia	8	01/07/2013	Closed - Follow Up Complete	N	
12/NW/0711	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Month Trial of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Mild to Moderate Alzheimer's Disease (TRx-237-015)	10	01/01/2014	Open	Y	Study has delivered to time and target.
12/NW/0802	A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by an active treatment period, to evaluate the efficacy, safety and tolerability of two doses of oral administration of laquinimod (0.6 mg/day)			Withdrawn	N/A	No Target and no Date agreed.
12/SC/0024	A 24month, phase IIIb, openlabel, single arm, multicenter study assessing the efficacy and safety of an individualized, stabilization criteriadriven PRN dosing regimen with 0.5mg ranibizumab intravitreal injections applied as monotherapy in patients	5	31/07/2012	Closed - In Follow Up	N	
12/SC/0025	A 24month, phase IIIb, openlabel, randomized, activecontrolled, 3arm, multicenter study assessing the efficacy and safety of an individualized, stabilizationcriteriadriven PRN dosing regimen with 0.5mg ranibizumab intravitreal injections applied as	7	28/02/2013	Closed - In Follow Up	N	
12/SC/0031	A Phase 3 Evaluation of BMS-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Subjects with Chronic Hepatitis C Genotype 4n (v1) - Clinical Protocol A1444042	2	30/04/2014	Closed - Follow Up Complete	Y	Date agreed to recruit to target not yet passed, but study has already delivered to time and target.
12/SC/0042	A Phase III, randomized, double-blind trial to evaluate the efficacy, safety and tolerability of TMC435 vs telaprevir, both in combination with PegIFN?-2a and ribavirin, in chronic hepatitis C genotype-1 infected subjects who were null or partial re	5	30/09/2012	Closed - In Follow Up	N	
12/SC/0435	Efficacy and safety of 3 doses of S 38093 (2, 5 and 20 mg/day) verusu placebo, in co-administration with donepezil (10mg/day) in patients with moderate Alzheimer's Disease	10	01/07/2013	Open	N	
12/SC/0538	A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Behavioral Variant Frontotemporal Dementia (bvFTD)	4	01/01/2014	Open	N	SIV delay.
12/SC/0540	A phase III, Randomised, Partially Double-Blind and Placebo-Controlled Study of BI 207127 in combination with Faldaprevir and Ribavirin in Treatment-Na?ve Patients with Chronic Genoptype 1 HCV Infection	3		Closed - Follow Up Complete	N	
12/SS/0007	A randomised Phase 2 Placebo-Controlled Study of LY2495655 in Patients with Advanced or Metastatic Pancreatic Cancer Receiving Chemotherapy	4	30/01/2014	Closed - In Follow Up	N	
12/SS/0028	The Sapheon Closure System (SCS) Kit - European Sapheon Closure System Observational ProjectivE (Escape) Observational Study	70	31/07/2012	Closed - In Follow Up	N	

12/WM/0341	A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular events When AMG 145 is Used in Combination With Statin Therapy in Patients with Clinically Evident	100	01/08/2014	Open	N/A	Date agreed to recruit to target not yet passed.
12/WS/0184	Multi-Center, Open-Label, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 or Investigators Choice in Subjects with Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)	3	15/06/2014	Open	N/A	Date agreed to recruit to target not yet passed.
12/YH/0179	A Companion Trial to Study GS-US-312-0116: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Rituximab as Therapy for Patients with Previously Treated Chronic Ly	5	01/05/2013	Open	N	
12/YH/0318	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia	5	01/06/2013	Open	Y	Study has delivered to time and target.
13//YH/0174	A Multicenter, Randomized, Double-Blind, Study Comparing the Efficacy and Safety of Continuing versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects with Non Radiographic Axial Spondyloarthritis			Withdrawn	N/A	No Target and no Date agreed.
13/EE/0199	An Exploratory Study of the Safety and Efficacy of BOTOX for the Treatment of Premature Ejaculation	10	01/08/2015	Open	N/A	Date agreed to recruit to target not yet passed.
13/EE/0257	A Phase II Clinical Trial to Study the Efficacy and Safety of a combination regimen of MK-5172 and MK-8742 with Ribavirin (RBV) in Subjects with Chronic Hepatitis C Genotype 2 Infection	1	28/02/2014	Closed - In Follow Up	Y	Study has delivered to time and target.
13/EE/0276	A Phase 3B Randomized, Open Label Multi Center Trial Assessing Sofosbuvir + Ribavirin for 16 or 24 Weeks and Sofosbuvir + Pegylated Interferon + Ribavirin for 12 Weeks in Subjects with Genotype 2 or 3 Chronic HCV Infection	4	01/01/2014	Open	Y	Study has delivered to time and target.
13/EE/0365	Investigation of newly developed 1- and 2-piece convex ostomy products in subjects with ileostomy			Withdrawn	N/A	No Target and no Date agreed.
13/EM/0374	A doubleblind, randomized, placebocontrolled, study to demonstrate the efficacy and safety of 250 mg or 1 g A3384 administered orally twice daily for two weeks to patients with Bile Acid Malabsorption (BAM)/Bile Acid Diarrhoea (BAD)			Open	N/A	No Target and no Date agreed.
13/LO/0006	A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects	5	31/07/2013	Closed - In Follow Up	Y	Study has delivered to time and target.
13/LO/0097	A phase 2b dose-ranging, randomized, double-blind, placebo controlled trial evaluating the safety and efficacy of GS-6624, a monoclonal antibody against Lysyl oxidase like molecular 2 (LOXL2) in subjects with advanced liver fibrosis but not cirrhosi	5		Withdrawn	N/A	Study burden on patients was excessive / heavy. Therefore discouraged patients from consenting. Study since closed by sponsor.
13/LO/0129	A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects	6		Open	N/A	No Date agreed with Sponsor.
13/LO/0206	A phase 3 evaluation of Daclatasvir in combination with Peginterferon Lambda-1a and Ribavirin (RBV) or Telaprevir in Combination with Peginterferon Alfa-2a and RBV in Patients with Chronic Hepatitis C Genotype 1b who are Treatment Na?ve or Prior R	4	01/11/2013	Closed - In Follow Up	N	
13/LO/0223	Protexo Registry - A combined retrospective and prospective post marketing surveillance study in patients using Temperature controlled Laminar Airflow (TLA)	400		Suspended	N/A	Study suspended by sponsor.
13/LO/0425	A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and BT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults with Genotype 1a Chronic Hepati	5	01/05/2013	Closed - In Follow Up	Y	Study has delivered to time and target.

13/LO/0501	A PHASE 2, RANDOMIZED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND ANTI-CYTOMEGALOVIRUS (CMV) ACTIVITY OF MARIBAVIR VERSUS VALGANCICLOVIR FOR TREATMENT OF CMV INFECTIONS IN TRANSPLANT RECIPIENTS WHO DO NOT HAVE CMV ORGAN DISEASE	1	31/03/2014	Closed - Follow Up Complete	N	Sponsor closed recruitment as study-wide recruitment completed.
13/LO/0535	A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis	3	31/12/2013	Open	Y	Study has delivered to time and target.
13/LO/0552	SinuSys Patency of Maxillary Sinus Ostia Study	6	01/06/2013	Closed - Follow Up Complete	Y	Study has delivered to time and target.
13/LO/0615	A Randomized, Controlled, Open-Label, Phase 2, Trial of SGI-110 and Carboplatin in Subjects with Platinum-Resistant Recurrent Ovarian Cancer	5	01/05/2014	Open	Y	Date agreed to recruit to target not yet passed, but study has already delivered to time and target.
13/LO/0740	A RANDOMIZED, MULTICENTER, DOUBLE BLIND PHASE 3 STUDY OF PD 0332991 (ORAL CDK 4/6 INHIBITOR) PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER (+), HER2 (-) BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR S			Open	N/A	No Target and no Date agreed.
13/LO/0830	Phase 3 open label study evaluating the efficacy and safety of pegylated interferon lambda-1a, in combination with ribavirin and daclatasvir, for treatment of chronic HCV infection with treatment naive genotypes 1, 2, 3 or 4 in subjects co-infected	2	30/04/2014	Open	N/A	Date agreed to recruit to target not yet passed.
13/LO/0855	A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Rituximab for Previously Treated Indolent Non-Hodgkin Lymphoma	15		Open	N/A	No Date agreed with Sponsor.
13/LO/1081	A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer	6	31/12/2018	Open	N/A	Date agreed to recruit to target not yet passed.
13/LO/1121	A Randomized, Controlled Phase 2 Study Evaluating LY2875358 plus Erlotinib versus Erlotinib as First Line Treatment in Metastatic Non Small Cell Lung Cancer Patients with Activating EGFR Mutations Who Have Disease Control after an 8 Week Lead In Tr	6	01/03/2015	Open	N/A	Date agreed to recruit to target not yet passed.
13/LO/1290	A Followup Study to Assess Resistance and Durability of Response to AbbVie DirectActing Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection			Withdrawn	N/A	Withdrawn by Sponsor due to recent results of a related study indicating that there would be need for fewer subjects to answer the study question.
13/LO/1302	A Phase IIb randomised, openlabel study of the safety and efficacy of dolutegravir/abacavir/lamivudine once daily compared to atazanavir and ritonavir plus tenofovir/emtricitabine once daily in HIV1 infected antiretroviral therapy naive women.	4	01/08/2014	Open	Y	Date agreed to recruit to target not yet passed, but study has already delivered to time and target.
13/LO/1332	A TwoPart Phase 1/2a, OpenLabel, Dose Escalation Study to Evaluate the Tolerability and Preliminary Antitumour Activity of OPB111001 in Patients with Advanced Cancers that are Poorly Responsive to Standard Anticancer Treatment	30		Open	N/A	No Date agreed with Sponsor.
13/LO/1352	A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) COMPARED WITH DOCETAXEL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AFTER PLATINUM FAILURE	2		Open	N/A	No Date agreed with Sponsor.
13/NE/0125	PRESTO Neo.1.C/E	8	01/08/2014	Open	N/A	Date agreed to recruit to target not yet passed.
13/NE/0177	A phase II, randomised, double-blind, placebo-controlled study to evaluate LUM001, an apical sodium-dependent bile acid transporter inhibitor (ASBTi), in combination with ursodeoxycholic acid (UDCA) in patients with primary biliary cirrhosis	3	01/03/2014	Open	N	
13/NW/0171	A Phase 2b, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Inhaled CVT-301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena)	5	01/02/2014	Closed - Follow Up Complete	N	
13/NW/0363	A Multicenter Openlabel Extension (OLE) Study to Assess the Long term Safety and Efficacy of AMG 145	8	01/01/2014	Open	N	

13/NW/0464	A PlaceboControlled, Multicenter, DoubleBlind, Randomized, Pharmacokinetic and Pharmacodynamic Trial of IDN6556 in Subjects with Acute on Chronic Liver Failure			Open	N/A	No Target and no Date agreed.
13/nw/0583	A 24-Week International, Multi-center, Randomized, Parallel-group, Double-blind Trial to Evaluate Metformin Extended Release Monotherapy Compared to Metformin Immediate Release Monotherapy in Adult Subjects with Type 2 Diabetes who have Inadequate G			Open	N/A	No Target and no Date agreed.
13/SC/0092	A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis (Protocol No: CBAF312A23			Open	N/A	No Target and no Date agreed.
13/SC/0146	A phase III, randomised, open label, activecontrolled study of an interferonfree regimen of BI 207127 in combination with Faldaprevir and Ribavirin compared to Telaprevir in combination with pegylated interferona and ribavirin in treatmentnaï	3	30/03/2016	Withdrawn	N/A	Date agreed to recruit to target not yet passed.
13/SC/0174	A phase 2b dose-ranging, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of GS-6624, a monoclonal antibody against lysyl oxidase like moleculae 2 (LOXL2) in subjects with Primary Sclerosing Cholangitis (PSC)	5	01/12/2013	Closed - Follow Up Complete	N	Study burden on patients was excessive / heavy. Therefore discouraged patients from consenting. Study since closed by sponsor.
13/SC/0249	A phase 2b dose-ranging, randomized, double-blind, placebo controlled trial evaluating the safety and efficacy of GS-6624, a monoclonal antibody against Lysyl oxidase like molecular 2 (LOXL2) in subjects with compensated cirrhosis secondary to non a	5		Closed - Follow Up Complete	N/A	No Date agreed with Sponsor.
13/SC/0259	A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas. Gilead GS-US-313-0125	5		Open	N/A	No Date agreed with Sponsor.
13/SC/0291	AN OPEN LABEL, PHASE I STUDY TO EVALUATE THE IMPACT OF SEVERE HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS AND SAFETY OF VEMURAFENIB IN BRAFV600 MUTATION POSITIVE CANCER PATIENTS			Withdrawn	N/A	No Target and no Date agreed.
13/SC/0311	A randomized, controlled, doubleblind Phase III trial to compare the efficacy, safety and pharmacokinetics of GP2013 plus cyclophosphamide, vincristine, prednisone vs. MabThera? plus cyclophosphamide, vincristine, prednisone, followed by GP2013	5		Open	N/A	No Date agreed with Sponsor.
13/SC/0348	A randomized, OpenLabel, Phase 2 Study Evaluating LY2875358 Plus Erlotinib and LY2875358 Monotherapy in MET Diagnostic Positive NSCLC Patients with Acquired Resistance to Erlotinib	6	01/12/2013	Open	N	Delayed Green Light.
13/SC/0360	A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa 2a and Ribavirin, Each Administered with Telaprevir in Subjects with Genotype-1 Chronic Hepatitis C who are Treatment-Naive or Relapsed on Tre	4	21/10/2013	Closed - In Follow Up	Y	Study has delivered to time and target.
13/SC/0383	A Two Part, Randomized Clinical Trial to Study Biomarkers of MK8237 (SCH 900237) Treatment in Subjects with House Dust Mite Induced Allergic Rhinitis or Rhinoconjunctivitis	17	30/06/2014	Open	N/A	Date agreed to recruit to target not yet passed.
13/SW/0124	A PERFORMANCE EVALUATION STUDY OF UROSENS? MCM5-ELISA FOR THE DETECTION OF PROSTATE CANCER IN PATIENTS WITH KNOWN DISEASE AND IN THOSE PRESENTING WITH RAISED SERUM PROSTATE-SPECIFIC ANTIGEN AND/OR ABNORMAL PROSTATE GLAND MORPHOLOGY	250		Open	N/A	No Date agreed with Sponsor.
13/WA/0064	A performance evaluation study of UROSENS Mcm5 ELISA test in the diagnosis of bladder cancer in patients presenting with haematuria and lower urinary tract symptoms with suspicion of malignancy	250	01/11/2013	Open	N	Has now met target of 250.
13/WA/0178	A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemcitabine in Combination With TH-302 Compared With Gemcitabine in Combination With Placebo in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable	5	01/07/2014	Open	N/A	Date agreed to recruit to target not yet passed.

13/WA/0328	Randomized controlled study comparing AEZS-108 with doxorubicin as second line therapy for locally advanced, recurrent or metastatic endometrial cancer	5	30/06/2015	Open	N/A	Date agreed to recruit to target not yet passed.
13/WM/0231	Safety of Nasal Influenza Immunisation in Egg Allergic Children The SNIFFLE study			Closed - Follow Up Complete	N/A	No Target and no Date agreed.
13/YH/0229	GO2: Alternative chemotherapy for frail or elderly patients with advanced gastric or oesophageal cancer.	6	28/02/2019	Open	N/A	Date agreed to recruit to target not yet passed.
13/YH/0275	Revitive for the treatment of venous insufficiency	20	01/07/2014	Open	N/A	Date agreed to recruit to target not yet passed.